BUSINESSFINANCIAL TIMES WORLD
How AstraZeneca’s $400bn tie-up with US rival Bristol Myers unravelled
The article details how a potential $400bn tie-up and merger between AstraZeneca and its US rival, Bristol Myers, ultimately unravelled. Had this mega-deal proceeded, it would have represented a notable return to major pharma megadeals.
Mentioned
Related Signal
Adjacent reporting
- FirstFT: AstraZeneca and Bristol Myers Squibb discuss $400bn tie-up
- AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
- AstraZeneca said to have explored Bristol Myers merger
- AstraZeneca stock sinks on reports of merger talks with Bristol Myers Squibb
- AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report